Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CanaQuest Medical Corp CANQF

Biotechnology
CanaQuest Medical Corp is a Canada-based clinical-stage, life sciences company. The Company is focused on the drug discovery and development of targeted therapeutics within the endocannabinoidome, including PPAR receptors. The Company is focused on treating neurological conditions, such as epilepsy, anxiety, depression, and post-traumatic stress disorder (PTSD). It has created a natural... see more

Recent & Breaking News (OTCPK:CANQF)

CanaQuest Announces Key Appointments to Team to Drive CQ-001 through Clinical Trials

GlobeNewswire June 11, 2024

NHL Alumni Association partners with CanaQuest and NEEKA Health to Conduct Studies for Anxiety and Quality of Life in former NHL Players

Accesswire October 31, 2023

CANAQUEST Announces Award of European Cannabinoid Patent

Accesswire September 19, 2023

CanaQuest Awarded Best Global Medical Cannabinoid Development Company 2023 by UK-based Global Health & Pharma for their 8th Annual Healthcare and Pharmaceutical Program

Accesswire July 26, 2023

CanaQuest and Neeka Health Sign Agreement to Conduct Clinical Studies with Mentanine(R)

Accesswire April 25, 2023

CanaQuest Achieves Statistically Significant Reduction of Seizures for Epilepsy Compared to Standard CBD

Accesswire December 8, 2022

Canaquest Launches Mentanine (R) (Cannabidiol + IP Formula) in the US via WWW.CANAQUESTSTORE.COM, Supported by Western University Pre-Clinical Trials Targeting Anxiety, Depression and PTSD

Accesswire September 8, 2022

CanaQuest Files International Mentanine(R) Patent, a Scientific CBD Formulation for Mental Health

Accesswire April 29, 2021

CanaQuest Medical Corp Appoints Investor Relations and PR Veteran Rob Rinderman as its New Director of Communications

Accesswire April 7, 2021

CanaQuest Medical Corp Honored With International CBD Life Science R & D Excellence Award 2020 by Global Health & Pharma

Accesswire March 29, 2021

Fundamental Research Corp Initiates Coverage on CanaQuest (CANQF) with Buy Rating and US$0.78 Fair Value Estimate

Accesswire March 23, 2021

CANAQUEST SIGNS MEDICINAL CANNABIS EDUCATION PARTNERSHIP WITH THE CANADIAN CANNABIS DISPUTE RESOLUTION CENTRE

GlobeNewswire March 11, 2021

CANAQUEST SIGNS MENTANINE® AND MENTABINOL® PRODUCTION AND DISTRIBUTION AGREEMENT WITH PURCANN PHARMA AND SILICYCLE INC.

GlobeNewswire February 2, 2021

CANAQUEST PRESIDENT INTERVIEWED BY THE WALL STREET ANALYZER

GlobeNewswire January 19, 2021

CANAQUEST ANNOUNCES MENTABINOL® A SCIENTIFIC DISCOVERY, AS PUBLISHED IN THE JOURNAL OF NEUROSCIENCE

GlobeNewswire December 3, 2020

CANAQUEST MEDICAL CORP SECURES APPROVAL FOR LISTING ON THE OCMX(TM), AN ONLINE INVESTOR AND FINANCIAL CONNECTION PORTAL

GlobeNewswire September 17, 2020

UPDATE: CANAQUEST MEDICAL CORP FILES PROVISIONAL PATENT FOR MENTANINE® - OMEGA-3 & PURE CANNABIDIOL ("CBD") FORMULATION BOOSTING MENTAL HEALTH EFFICACY WHILE MINIMIZING CBD DOSAGE

GlobeNewswire July 14, 2020

CANAQUEST MEDICAL CORP FILES PROVISIONAL PATENT FOR MENTANINE® - OMEGA-3 & PURE CANNABIDIOL ("CBD") FORMULATION BOOSTING MENTAL HEALTH EFFICACY WHILE MINIMIZING CBD DOSAGE

GlobeNewswire July 14, 2020

Canaquest Medical Corp Awaits Health Canada Approval for Sales and Export of Mentabinol®

GlobeNewswire February 6, 2020

CanaQuest Medical Corp. Joins Stock Day Podcast to Discuss Global Expansion Plans

Newsfile November 25, 2019